

Special Issue

Fracture-Related Infection: An Update on Antimicrobial Therapy

Message from the Guest Editors

Fracture-related infection (FRI) is one of the most complex problems in orthopedic trauma surgery. It is a serious complication that can have an important impact on patients. In recent decades, the problem of orthopedic device-related infection has gained significant attention; however, this has primarily focused on periprosthetic joint infection (PJI), rather than on FRI. The lack of scientific data, with respect to diagnostic and treatment principles of FRI, has hampered the development of an evidence-based approach for prevention, diagnosis and treatment of this entity. With this Special Issue on FRI, and as members of the *FRI consensus group*, we therefore would like to focus on an aspect of FRI that often has not received sufficient attention in the surgical world, namely, antimicrobial therapy. This issue welcomes submissions within the following scientific fields: basic research, translational research, clinical research and reviews. Key opinion leaders in the field will peer review all manuscripts and consider if they are eligible for publication.

Guest Editors

Prof. Dr. Willem-Jan Metsmakers

Department of Trauma Surgery, University Hospitals Leuven, 3000 Leuven, Belgium

Prof. Dr. Werner Zimmerli

Interdisciplinary Unit of Orthopaedic Infections, Kantonsspital Baselland, 4410 Liestal, Switzerland

Dr. Fintan Moriarty

AO Research Institute Davos, 7270 Davos Platz, Switzerland

Deadline for manuscript submissions

closed (30 June 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/86178

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)